{"id":5678,"date":"2013-06-20T10:02:45","date_gmt":"2013-06-20T15:02:45","guid":{"rendered":"https:\/\/www.bad-drug.net\/?p=5678"},"modified":"2013-06-20T10:02:45","modified_gmt":"2013-06-20T15:02:45","slug":"fda-holds-meeting-on-hiv-cure-research","status":"publish","type":"post","link":"https:\/\/www.bad-drug.net\/bad-drug-blog\/fda-holds-meeting-on-hiv-cure-research","title":{"rendered":"FDA Holds Meeting on HIV Cure Research"},"content":{"rendered":"

On June 14, 2013 The U.S. Food and Drug Administration (FDA<\/strong>) held a public meeting\u00a0on\u00a0HIV (human immunodeficiency virus)<\/strong>\u00a0patient-focused drug development and cure research, <\/strong>in\u00a0Silver Spring,\u00a0Maryland.\u00a0The FDA sees to it that drugs are safe and used effectively by enforcing the Food, Drug, and Cosmetic Act as well as the Public Health Service Act.<\/p>\n

Patients affected with the virus drove the discussion. The FDA was interested in getting the patient’s perspective in terms of how HIV impacts their daily life, current available therapies to treat the virus, and cure research.<\/p>\n

Topics and Questions<\/h2>\n

The panelist started off the discussion to begin a facilitated \u00a0dialogue between the guests and audience members upon the presentation of each subject. Topic 1 was patients<\/strong>\u2019 perspective<\/strong> on current approaches to managing HIV and on symptoms experienced because of HIV or its treatment<\/strong>. The questions included:<\/p>\n